China, Merck and HPV
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Hosted on MSN1d
Truist Securities Downgrades Merck (MRK)Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.
EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...
Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $101.02 which represents a slight increase of $1.30 or 1.30% from the prior close of $99.72. The stock opened at $100.13 and touched a ...
MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and ...
Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...
M-Trust – which is now in beta test release mode – is described by the company as a "cyber-physical trust platform." ...
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise ...
The winners of ‘Best African Women Researchers Awards’ and ‘Best Young African Researcher Awards’ will be enrolled into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback